Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SELARL PHARMACIE CHENEL-PRIE : revenue, balance sheet and financial ratios

SELARL PHARMACIE CHENEL-PRIE is a French company founded 9 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in CORPS-NUDS (35150), this company of category PME shows in 2025 a net income positive of 102 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL PHARMACIE CHENEL-PRIE (SIREN 828276295)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018
Revenue N/C N/C N/C N/C N/C N/C N/C N/C
Net income 102 080 € 82 492 € 101 575 € 151 583 € 133 909 € 134 334 € 123 119 € 72 110 €
EBITDA N/C N/C N/C N/C N/C N/C N/C N/C
Net margin N/C N/C N/C N/C N/C N/C N/C N/C

Revenue and income statement

In 2025, SELARL PHARMACIE CHENEL-PRIE generates positive net income of 102 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2018-2025: 72 k€ -> 102 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

102 080 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 40%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 60%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

40.435%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

60.087%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

43.0%

Solvency indicators evolution
SELARL PHARMACIE CHENEL-PRIE

Sector positioning

Debt ratio
40.44 2025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Good -10 pts over 3 years

In 2025, the debt ratio of SELARL PHARMACIE CHENEL-PRIE (40.44) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
60.09% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Good +8 pts over 3 years

In 2025, the financial autonomy of SELARL PHARMACIE CHENEL-PRIE (60.1%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 230.62. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

230.618

Liquidity indicators evolution
SELARL PHARMACIE CHENEL-PRIE

Sector positioning

Liquidity ratio
230.62 2025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Good -9 pts over 3 years

In 2025, the liquidity ratio of SELARL PHARMACIE CHENEL-PRIE (230.62) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Positioning of SELARL PHARMACIE CHENEL-PRIE in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of SELARL PHARMACIE CHENEL-PRIE is estimated at 1 621 552 € (range 1 100 393€ - 2 544 439€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
1100k€ 1621k€ 2544k€
1 621 552 € Range: 1 100 393€ - 2 544 439€
NAF 5 année 2025

Valuation method used

Net Income Multiple
102 080 € × 15.9x = 1 621 553 €
Range: 1 100 393€ - 2 544 440€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE CHENEL-PRIE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL PHARMACIE CHENEL-PRIE

What is the revenue of SELARL PHARMACIE CHENEL-PRIE ?

The revenue of SELARL PHARMACIE CHENEL-PRIE is not publicly disclosed (confidential accounts filed with INPI).

Is SELARL PHARMACIE CHENEL-PRIE profitable?

Yes, SELARL PHARMACIE CHENEL-PRIE generated a net profit of 102 k€ in 2025.

Where is the headquarters of SELARL PHARMACIE CHENEL-PRIE ?

The headquarters of SELARL PHARMACIE CHENEL-PRIE is located in CORPS-NUDS (35150), in the department Ille-et-Vilaine.

Where to find the tax return of SELARL PHARMACIE CHENEL-PRIE ?

The tax return of SELARL PHARMACIE CHENEL-PRIE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE CHENEL-PRIE operate?

SELARL PHARMACIE CHENEL-PRIE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.